Compare AGX & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGX | STOK |
|---|---|---|
| Founded | 1961 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 1.9B |
| IPO Year | N/A | 2019 |
| Metric | AGX | STOK |
|---|---|---|
| Price | $328.05 | $32.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $321.00 | $33.11 |
| AVG Volume (30 Days) | 414.2K | ★ 910.0K |
| Earning Date | 12-04-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | ★ 76.74 | N/A |
| EPS | ★ 8.49 | 0.68 |
| Revenue | ★ $915,030,000.00 | $205,632,000.00 |
| Revenue This Year | $11.43 | $430.24 |
| Revenue Next Year | $18.27 | N/A |
| P/E Ratio | ★ $38.64 | $46.98 |
| Revenue Growth | 13.49 | ★ 1128.17 |
| 52 Week Low | $101.02 | $5.35 |
| 52 Week High | $399.30 | $38.69 |
| Indicator | AGX | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 49.44 | 53.64 |
| Support Level | $290.10 | $31.50 |
| Resistance Level | $343.95 | $33.90 |
| Average True Range (ATR) | 19.06 | 2.25 |
| MACD | -1.05 | -0.15 |
| Stochastic Oscillator | 76.81 | 38.02 |
Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Telecom Services, out of which Power Services derives the majority of revenue.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.